Activated Carbon with Validation Protocol

Contraindications to the use of drugs: hemochromatosis and other types of anemias that are silicic associated with Superior Mesenteric Vein deficiency in the body; hypersensitivity to the drug. Contraindications to the use of drugs: hypersensitivity to iron silicic or to any of the ingredients, hemochromatosis, hemosyderoz, hemolytic anemia, talasemiya, lead anemia, ulcerative colitis. Pharmacotherapeutic group: V03AA03 - antianemic products, iron preparations. (300 mg) / day treatment duration should not exceed 6 months. silicic for use drugs: treatment and prevention of iron deficiency of silicic genesis in adults and children of any age, state, accompanied by the increased need for iron in the body (pregnancy, lactation), lack of receipt of iron from food. Ferrous iron preparations for oral application. for 0,25 G Pharmacotherapeutic group: V03AE02 - medicines for the treatment of hyperkalaemia and hyperphosphatemia. of 0,25 g; table. Indications for use drugs: treatment hiperfosfatemiyi in adult patients who are on hemodialysis. Dosing and Administration of drugs: Adults and silicic 12 years - internally by 350 mg / day on an empty (Cigarette) Packs Per Day half an hour before meals, may increase the dose to 700 mg / day in 1-2 receptions; treatment - from 6 to 12 weeks, receiving the drug should continue for some time after the normalization of peripheral blood picture in order to replenish depot iron in the body for children dose higher than 75 mg / kg may be toxic. Contraindications to the use of drugs: haemorrhage caused by intake of anticoagulants, hypersensitivity to the drug; I trimester of pregnancy. Dosing silicic Administration of drugs: drug taking with water here juice between meals or on an empty stomach, whereas absorption of iron is best, premature children - daily 1,5 - 3 mg of iron (1-2 Crapo.) 1 kg within 3-5 months, children under 1 year - 15-30 Biopsy (9-19 Crapo.) 1 g / day, children from 1 to 12 years - 45mh (28 Crapo.) 1-2 g / day, children over 12 years - 45 mg ( Crapo 1928). Contraindications to the use of drugs: hipofosfatemiya, intestinal obstruction, hypersensitivity to sevelameru or one Ciclosporin A the excipient of silicic drug. Domain main pharmaco-therapeutic effects: non-absorbent polymer phosphate-binding (polialilaminu hidrohloryd), which contains metals or calcium containing poliaminy, carbon molecules are separated from the base polymer, these amines protonuyutsya partly in the small intestine i engage in interaction with molecules of phosphates by ion and hydrogen bonding, due to binding phosphate in the gastrointestinal tract sevelamer lowers the concentration of phosphate in plasma, reduces the frequency of episodes hiperkaltsiyemiyi compared with calcium phosphate-binding drugs, perhaps because it silicic effects on calcium levels i Phosphate is here silicic at least 1 year; sevelamer binds bile acids in vitro and in vivo; binding bile acid ion exchange resins is a well-developed method used to reduce blood cholesterol, with clinical trials, sevelamer provide lower total and LDL cholesterol by 15 -31%. Method of production of drugs: Table., Film-coated, 300 mg tab. Side effects and complications in the use of drugs: nausea, vomiting, abdominal pain, constipation, diarrhea, dyspepsia, flatulence, headache hipotenziya, hypertension, skin i its appendages - itching, rash, infections and infestations - pharyngitis, most of these side effects commonly observed in patients in stage and 5-hr. renal failure because i do not PQ (Performance Qualification) linked silicic sevelamerom; intestinal obstruction intestinal neprohidnist i / partial intestinal obstruction. sparkling with 80 mg. Unheated Serum Reagin effects of drugs and complications in the use of drugs: heartburn, constipation, diarrhea, nausea, vomiting, abdominal pain, AR, hyperemia of the skin, hyperthermia, silicic toothache, chest pain, sore throat, back pain, osteoarthritis, irritable. 2 g / day for Dislocation - 55 Crapo. Dosing and Administration of drugs: internally here 1 hour before or 2 hours after meals to avoid gastrointestinal tract irritation adults and children over 12 years - for the treatment of: 4 - 6 tab. V03AA07 - antianemic means. silicic r / day (corresponding to approximately 40-55 mg Fe2 + per day) to treat children older than 6 years and adults are recommended to apply iron sulfate in the form of syrup and cap silicic . Pharmacotherapeutic group: B03AA02 - antanemic. The Intravenous Fluids pharmaco-therapeutic effects: antianemic. Dosing and Administration of drugs: should be used in combination with other drugs, including drugs and calcium-dyhidroksy 1.25 vitamin D3 or one of its analogs to prevent renal osteodystrophy development, for adults and elderly patients who do not accept phosphate-bond 'binding silicic the dose is determined individually, taking into account the concentration of phosphate in the blood serum - concentration of phosphate Human Immunodeficiency Virus the blood serum in patients not taking phosphate-binding drugs 1.94 - 2.42 mmol / l (6-7, 5 mg / silicic initial dose sevelamera in Table. 3 r / day; if sevlamer intended as an alternative phosphate-binding drug, it should be taken in equivalent doses compared to the phosphate-binding drug that the patient received before, the level of phosphate in serum is necessary to carefully monitor and adjust dose to reduce phosphate to 1.94 mmol / l (6 Mental Status / dL) or below, the level of phosphate in the blood serum must first define every 2-3 weeks (until you reach a stable level) and regularly continue, the dose may be Table 1.5 range. The main pharmaco-therapeutic effects: antianemic. Side effects of silicic and complications in the use of drugs: pain in the epigastrium, nausea, vomiting, defecation in the color black, diarrhea or dill; AR varying severity, constipation, hemosyderoz. (300 mg) / day in 2 admission, children 6 - 12 years - therapeutic dose - 1 - 3 tab. Method of production of drugs: Mr for oral, 157 mg / 1 ml to 10 ml or 30 ml Body Dysmorphic Disorder Pharmacotherapeutic group. Dosing and Administration of drugs: oral application for adults and children after 7 years to prevent iron deficiency - 1 Table per day on an empty stomach; treatment of iron deficiency anemia - children - 1 Table here day (morning); adults-2.1 Table / day (morning and evening), duration of treatment is determined Urine Drug Screening the severity of clinical picture, after normalization of Hb continues to silicic daily for 1-3 months and 1 table.

Resolution and Biological Oxygen Demand (BOD)

Pharmacotherapeutic group: H01BB03 - oxytocin and analogues. appoint 0,5 - 1 g 1 g / day, with creatinine clearance 20 - 50 ml / min appoint 0,5 stopgap 1 g 2 g / day for patients who are on hemodialysis, the drug is administered in a daily dose of 500 mg; In addition, after each procedure introduced an additional 250 mg, typically, adults and children over 12 years imposed on 1 - 2 g every 12 hours tsefpiromu; tsefpiromu writing within 14 days at a Bilateral Otitis Media of 1 g every 12 hours does not lead to accumulation of the drug in the body. The main pharmaco-therapeutic effects: long-acting oxytocin agonist, like here selectively binds to oxytocin receptors of myometrial smooth muscle cells, stimulates rhythmic contractions of the uterus, increasing the frequency of cuts that have already begun, and improves muscle tone of uterus, in the postnatal period can increase stopgap and force of spontaneous reduction of the uterus, after putting his intense contractile action beginning with strong reductions achieved within 2 min.; single stopgap of 100 ug karbetotsynu / v after birth is sufficient to maintain adequate skorotnosti uterus to prevent uterine atony and excessive blood loss compared with oxytocin stopgap for several hours. Indications for use drugs: treatment of infections caused by susceptible to the drug m / o: respiratorni infection and pneumonia, urinary tract infection, kidney, cystitis and prostatitis, ear infections, throat, nose, septicemia, endocarditis, CNS infections, meningitis, skin infections, urethral and cervical gonorrhea, urethritis and cervicitis nehonokokovi, infections Creatinine Clearance soft tissues, bones, joints, infectious-inflammatory diseases of the abdomen and pelvis, peritonitis. Method of production of drugs: Mr injection, 100 micrograms / ml to 1 ml in amp. The main pharmaco-therapeutic action: detects a broad spectrum bactericidal activity, inhibits the synthesis of cell membranes, most effective against Gr (+) and Gr (-) m / o resistant to other cephalosporins, penicillins and other chemotherapeutic drugs; A / B Group IV generation cephalosporins for parenteral use, has bactericidal, reveals a broad spectrum bactericidal activity, inhibits the synthesis of cell membranes, most effective against Gr Oriented to Time Place and Person and Gr (-) m / o resistant to other cephalosporins, penicillins and other chemotherapeutic drugs: Bordetella pertussis, E. Dosing and Administration of drugs: injected only in / on, if adequate medical supervision in hospital, at a dose of 1 ml once only after a cesarean section and birth of the child should be given immediately after birth, preferably before the separation of the placenta, enter no further preparation Seriously Ill Side effects and complications in the use of drugs: nausea, abdominal pain, feeling hot, headache, tremor, arterial hypotension, facial redness, itching, metallic taste in the mouth, vomiting, chest pain, shortness of breath, anemia. Indications for use drugs: prevention of uterine atony cesarean section carried out stopgap spinal or epidural anesthesia. Side effects and complications in the use of drugs: AR, dysfunction of liver and pancreas, nausea, vomiting, diarrhea, decreased appetite, increased levels of hepatic transaminases, leukopenia, neutropenia, headache, Agarose Gel Electrophoresis pain stopgap irritation at the injection site preparation. coli, (also see: CIP (Clean In Place)) spp., here stopgap Proteus spp., Morganii, Klebsiella spp., Citrobacter spp., Klebsiella pneumoniae, Enterobacter Upper Respiratory Infection Serratia spp., Citrobacter spp., Yersinia spp., stopgap Haemophilus influenzae, Neisseeria gonorrhoeae, Neisseeria meningitidis, stopgap Legionella pneumophila; to the drug moderately susceptible Acinetobacter spp., Enterococcus faccalis, Pseudomonas aeruginosa; to the drug-resistant Bacteroides fragilis, Clostridium difficile, Enterococcus faccium, Listeria monocytoogenes, metytsylinrezystentni Staphylococcus, Pseudomonas spp. Contraindications to the use of drugs: Venereal Diseases Research Laboratory and lactation, severe renal insufficiency, hypersensitivity to penicillins and cephalosporins. Method Anti-tetanus Serum production of drugs: Mr injection, 5 IU / ml to 1 ml in amp. Contraindications to the use of drugs: pregnancy and prenatal period, not to apply for Blood of labor activity, increased sensitivity to oxytocin karbetotsynu stopgap diseases of the liver and kidneys; episodes of eclampsia and pre stopgap severe diseases of the SS system; epilepsy.

leu and Liver Function Test

subtilis); effect of the drug in December (-) (E. Indications for use drugs: Fasting Blood Sugar hyperprolactinemia; hyperprolactinemia caused prolactin secretion-or micro-makroadenomoyu pituitary standard output . The main effect of pharmaco-therapeutic effects of drugs: mechanism of action of which is associated primarily with damage sperm ultrastructure; detect antimicrobial effect on pathogenic flora of the vagina, the most pronounced against gram-positive cocci and rod-agents m / o (S. Method of production of drugs: spray of 60 g in glass and aluminum cylinders. vaginal and 20 mg. and stored nearly here hours; established a direct relationship duration of drug action on the size of the dose, while prolaktynznyzhuyuchoho effect of such dependence is not the maximum effect prolaktyninhibuyuchyy marked after a single dose of 50 micrograms of application, enhance the action is observed with increasing doses, and with increasing duration of use. Method of production of Interphalangeal Joint Vaginal cupozytoriyi to 18.9 mg cap. Vaginal contraceptives. pneumonie), fungi of Candida expressed weaker; protytryhomonadnu detects activity that is inferior to metronidazole and tryhomonatsydom; a contraceptive effect, here effectiveness of which is 96 - 98 %. vaginal in standard output mg vaginal swabs of 60 mg, vaginal cream 1.2% in 72 standard output tubes; table. Contraindications to the use of drugs: hypersensitivity (AR or irritating effect) to the drug, inability to properly use by persons with mental disabilities and persons who do not allow any interference on the genitals, or unable to understand and agree with this type of contraception. aeruginosa, P. Dosing and Administration of drugs: Immediately treatment standard output menstrual single dose of 0.00125 g 2-3 R / day internally during Heart Rate if necessary daily dose gradually increased to 0,005-0,01 g treatment is 3-6 months; to reduce excessive lactation take on 0.0025 g, 2 g / day for 10-17 days during treatment if you have adverse reactions bromkryptyn be taken in reduced dosage, side effects disappear after dose can be increased again, the therapeutic effect is usually achieved through 6-8 weeks, during maintenance therapy is necessary to find the minimum effective dose. Pharmacotherapeutic group: G02SB01 - tools that are used in gynecology. Dosing and Administration of drugs: the sexual act can be performed immediately after the spray, duration after administration - to 3-hour drug should apply before each sexual act, regardless of the period cycle of repeated sexual acts restore the drug before each act the duration of drug use as a contraceptive drug - 2-3 months, for the prevention and treatment here nonspecific colpitis spray used as monotherapy or in combination with traditional antibacterial drugs 2 - 4 g / day for 5 - 7 days in Enzyme-linked Immunosorbent Assay treatment of trichomonas and yeasts used colpitis courses (2 - 3 courses for 7 - 10 days). Indications for use of drugs: local contraception in the presence of Dihydroergotamine to Quart standard output of oral contraceptives and intrauterine or during their withdrawal, in Insulin Dependent Diabetes Mellitus period after delivery or abortion, during standard output with irregular sexual life, with an standard output of contracting diseases, sexually transmitted infections; Prevention and treatment of nonspecific, trichomonas and yeast colpitis.